Clinical Trial

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B), participants will be randomly assigned to either Arm A or Arm B for the treatment of metastatic colorectal cancer. The primary objectives of this study is to compare the effecacy of treatment with trifluridine / tipiracil plus panitumumab versus trifluridine / tipiracil plus bevacizumab.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-12; most recent amendment 2024-02-14.
Status change: Not Yet Recruiting → Recruiting 2022-07-20
Trial Details
NCT Number NCT05007132
Lead Sponsor Dominik Paul Modest
Conditions Metastatic Colorectal Cancer
Enrollment 153 participants
Start Date 2021-12-17
Primary Completion 2029-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2024-02-15